Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.

摘要: Abstract Background & Aims: Tumor necrosis factor (TNF) is a pivotal cytokine in intestinal inflammation. Controlled trials using chimeric anti-TNF antibody (infliximab) have shown its efficacy refractory Crohn's disease. Methods: Endoscopic and histological response to infliximab was investigated multicenter, randomized, double-blind, placebo-controlled trial including 30 patients with active disease undergoing ileocolonoscopy before 4 weeks after intravenous administration of 5, 10, or 20 mg/kg placebo as single infusion. Lesions were scored by means the validated Disease Index Severity (CDEIS). biopsy specimens taken during both procedures from 9 gastrointestinal pathologist. Results: CDEIS scores decreased significantly most infliximab-treated without an apparent dose response. No endoscopic improvement observed group. The changes correlated highly those Activity Index. At level, disappearance inflammatory infiltrate but not placebo-treated ones; however, architectural persisted patients. Strictures developed several Conclusions: Clinical therapy accompanied significant healing lesions mucosal infiltrate. GASTROENTEROLOGY 1999;116:1029-1034